Figure 5.

Established rheumatoid arthritis: inflammation and joint destruction. Mean change from baseline to week 54 in modified van der Heijde–Sharp score among patients who remained clinical nonresponders from week 2 through week 54, by treatment group. Corresponding median changes in the methotrexate (MTX)-plus-placebo-treated group (placebo) and the groups receiving infliximab (IFX) 3 mg/kg every 8 weeks plus MTX, IFX 3 mg/kg every 4 weeks plus MTX, IFX 10 mg/kg every 8 weeks plus MTX, and IFX 10 mg/kg every 4 weeks plus MTX, as well as all IFX-plus-MTX groups were 3.50, 0.27, –0.50, –0.25, 1.25 and 0.00, respectively. *P <0.05, **P <0.01 versus MTX-plus-placebo-treated patients. Dosage and frequency data (4 weeks, 8 weeks) refer to infliximab treatment. Modified with permission from [33].

Smolen and Emery Arthritis Research & Therapy 2011 13(Suppl 1):S2   doi:10.1186/1478-6354-13-S1-S2